SCHEMBL2755832

SCHEMBL2755832

CNc1ccc(C)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.58
APP P05067 2/20 0.53
EPHX1 P07099 2/20 0.50
ALDH1A1 P00352 2/20 0.47
CYP3A4 P08684 1/20 0.47
L3MBTL4 Q8NA19 1/20 0.46
L3MBTL3 Q96JM7 1/20 0.46
LPAR1 Q92633 5/20 0.45
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 1/20 0.43
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
AHR P35869 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31239085 0.83 ACHE (0.58) ACHEAPPALDH1A1CYP3A4MEN1
SCHEMBL2755820 0.83 ACHE (0.58) ACHEAPPALDH1A1CYP3A4MEN1
SCHEMBL19682008 0.81 CA2 (0.53) APPALDH1A1HPGDPOLBLMNA
SCHEMBL8117764 0.81 ACHE (0.56) ACHEEPHX1ALDH1A1CYP3A4L3MBTL4
SCHEMBL11823159 0.81 ACHE (0.56) ACHEEPHX1ALDH1A1CYP3A4L3MBTL4
SCHEMBL11419004 0.81 ACHE (0.56) ACHEEPHX1ALDH1A1CYP3A4LPAR1
SCHEMBL16404492 0.80 HPGD (0.55) APPALDH1A1CYP3A4HPGDMEN1
SCHEMBL1547457 0.78 ALDH1A1 (0.61) APPALDH1A1CYP3A4HPGDNPC1
SCHEMBL171843 0.78 ACHE (0.52) ACHEEPHX1ALDH1A1CYP3A4LPAR1
SCHEMBL14258683 0.78 ACHE (0.52) ACHEEPHX1ALDH1A1CYP3A4L3MBTL4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 EP disclosed
US-20200392550-A1 REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS THE SCRIPPS RESEARCH INSTITUTE 2020-12-17 US disclosed
EP-3151669-B1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-10-28 EP disclosed
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-09-10 US disclosed
WO-2020071911-A1 PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-04-09 WO disclosed
EP-2791137-B1 PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2019-01-23 EP disclosed
WO-2019014267-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF Synthorx, Inc. (US) 2019-01-17 WO disclosed
US-20170217970-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2017-05-25 US disclosed
US-8383813-B2 Fused pyrrolocarbazoles CEPHALON, INC. (US) 2013-02-26 US disclosed
US-20120004253-A1 Novel Fused Pyrrolocarbazoles CEPHALON, INC. (US) 2012-01-05 US disclosed
US-7494987-B2 Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217970-A1 NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF ERBB2, JAK2, ERBB4 ACHE 4710/4885APP 4728/4885EPHX1 3379/4885
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 ACHE 2757/4885APP 1217/4885EPHX1 3902/4885
US-20120004253-A1 Novel Fused Pyrrolocarbazoles PC, PYCR1, CYP11B2 ACHE 1666/4885APP 2233/4885EPHX1 1347/4885
US-20200392550-A1 REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS RNGTT, MAX, POLRMT ACHE 3930/4885APP 2976/4885EPHX1 4411/4885
US-20200283398-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 ACHE 3885/4885APP 3438/4885EPHX1 807/4885
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 ACHE 3885/4885APP 3438/4885EPHX1 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.